U.S. markets open in 2 hours 44 minutes
  • S&P Futures

    4,422.50
    -15.50 (-0.35%)
     
  • Dow Futures

    34,562.00
    -82.00 (-0.24%)
     
  • Nasdaq Futures

    15,230.00
    -73.50 (-0.48%)
     
  • Russell 2000 Futures

    2,245.80
    -9.40 (-0.42%)
     
  • Crude Oil

    73.34
    +0.04 (+0.05%)
     
  • Gold

    1,755.40
    +5.60 (+0.32%)
     
  • Silver

    22.65
    -0.03 (-0.15%)
     
  • EUR/USD

    1.1734
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    1.4100
    0.0000 (0.00%)
     
  • Vix

    19.83
    -1.04 (-4.98%)
     
  • GBP/USD

    1.3704
    -0.0017 (-0.12%)
     
  • USD/JPY

    110.4390
    +0.1380 (+0.13%)
     
  • BTC-USD

    42,186.69
    -1,570.05 (-3.59%)
     
  • CMC Crypto 200

    1,042.32
    -66.61 (-6.01%)
     
  • FTSE 100

    7,062.23
    -16.12 (-0.23%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Nabriva Therapeutics Stock Gains On Positive Lefamulin Data In CABP Patients In China

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Nabriva Therapeutics (NASDAQ: NBRV) and its collaborating partner in China, Sinovant Sciences, have announced positive topline results from Sinovant's Phase 3 bridging study evaluating lefamulin in Chinese adults with community-acquired bacterial pneumonia (CABP).

  • Lefamulin met the primary endpoint of non-inferiority versus moxifloxacin, a broad-spectrum antibiotic for Investigator Assessment of Clinical Response at Test of Cure (IACR-TOC).

  • IACR-TOC is defined as the resolution or improvement of a subject's clinical signs and symptoms without any additional antibacterial therapy.

  • Success rates of 76.8% (n = 63/82) for lefamulin and 71.4% (n = 30/42) for moxifloxacin was observed.

  • IACR-TOC in the clinically evaluable population, success rates were 86.0% (n = 49/57) and 86.2% (n = 25/29) in the lefamulin and moxifloxacin arms, respectively.

  • lefamulin was observed to be generally safe and well-tolerated, with an overall rate of treatment-emergent adverse events comparable to that of moxifloxacin.

  • In addition, Sinovant has entered into an agreement with Sumitomo Pharmaceuticals (Suzhou) Co Ltd, a wholly-owned subsidiary of Sumitomo Dainippon Pharma (OTC: DNPUF), to acquire development and commercialization rights for lefamulin in Greater China.

  • Lefamulin (marketed by Nabriva in the U.S. as Xenleta) is a semi-synthetic pleuromutilin antibiotic for systemic administration.

  • Price Action: NBRV shares are up 60.1% at $2.37 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.